Verastem Inc.

10/17/2024 | Press release | Distributed by Public on 10/16/2024 23:10

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.